Validation externe des scores pronostiques de la Covid-19 en hospitalisation : une étude de cohorte multicentrique

Lombardi, Yannis; Azoyan, L.; Szychowiak, Piotr; Bellamine, Ali; Lemaître, Guillaume; Bernaux, Mélodie; Daniel, Castro; LeBlanc, Jason J.; Riller, Quentin; Steichen, Olivier

doi:10.1016/j.revmed.2021.10.297

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study evaluated the COVID-NoLab and COVID-SimpleLab risk scores in a French population of 14,343 inpatients and found AUROC values similar to those in the Quebec population (0.70 for COVID-NoLab and 0.71 for COVID-SimpleLab). 8 For the COVID-NoLab score, mortality rates were 1.5% in the low-risk group, 14.6% in the moderate-risk group, and 31.1% in the high-risk group. For the COVID-SimpleLab score, the mortality rates were 2.4% in the low-risk group, 12.8% in the moderate-risk group, and 28.2% in the high-risk group.…”

Section: Discussionmentioning

confidence: 92%

External Validation of the COVID-NoLab and COVID-SimpleLab Prognostic Tools

et al. 2022

View full text Add to dashboard Cite

Our objective was to externally validate 2 simple risk scores for mortality among a mostly inpatient population with COVID-19 in Canada (588 patients for COVID-NoLab and 479 patients for COVID-SimpleLab). The mortality rates in the low-, moderate-, and high-risk groups for COVID-NoLab were 1.1%, 9.6%, and 21.2%, respectively. The mortality rates for COVID-SimpleLab were 0.0%, 9.8%, and 20.0%, respectively. These values were similar to those in the original derivation cohort. The 2 simple risk scores, now successfully externally validated, offer clinicians a reliable way to quickly identify low-risk inpatients who could potentially be managed as outpatients in the event of a bed shortage. Both are available online (https://ebell-projects.shinyapps.io/covid_nolab/ and https://ebell-projects.shiny apps.io/COVID-SimpleLab/).

show abstract

Section: Discussionmentioning

confidence: 92%

External Validation of the COVID-NoLab and COVID-SimpleLab Prognostic Tools

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Numerous markers and scoring systems have been studied for COVID-19 as predictors of disease severity and poor prognosis (6)(7)(8)(9)(10). The aspartate aminotransferase-to-platelet ratio index (APRI) and the fibrosis-4 (FIB-4) scores are two of these that are readily applicable.…”

mentioning

confidence: 99%

The Role of APRI, FIB-4, and SAD-60 Scores as Predictors of Mortality in COVID-19 Patients

Copur¹,

Sürme²,

Tuncer³

et al. 2023

Infect Dis Clin Microbiol

View full text Add to dashboard Cite

Objective: Predictors of mortality that indicate disease severity plays an important role in COVID-19 management and treatment decisions. This study aimed to investigate the association between fibrosis-4 (FIB-4) score, aspartate aminotransferase-to-platelet ratio index (APRI), and novel biomarker-based score (SAD-60) with mortality in COVID-19 patients treated in a tertiary hospital. Materials and Methods: In this single-center retrospective study, patients ≥18 years of age who were admitted to our hospital for COVID-19 between December 1 and 31, 2021, were included. Patients were divided into two groups as deceased and survived. A comparative analysis was applied. Predictive abilities of the FIB-4, APRI, and SAD-60 scores for in-hospital mortality were evaluated. Results: Of the 453 patients enrolled in the study, 248 (54.6%) were male, and the mean age was 52.2±14.7 years. Mortality was recorded in 39 (8.5%) of the patients. The median values of APRI (0.43 and 0.58; p=0.001), FIB-4 score (1.66 and 2.91; p<0.001), and SAD-60 (2 and 8.25; p<0.001) were higher in deceased patients than in survivors. The optimal cut-off value for predicting mortality in the receiver operating characteristic (ROC) curve analysis was 0.58 for APRI (sensitivity=56.4%, specificity=63.6%); 2.14 for FIB-4 score (sensitivity=79.5%, specificity=68.2%); 4.25 for SAD-60 (sensitivity=90%, specificity=73.8%). In Cox regression analysis with a model that included gender, chronic obstructive pulmonary disease (COPD), and coronary artery disease (CAD), FIB-4 (hazard ratio [HR]=4.013, 95% confidence interval [CI]=1.643-9.803; p=0.002), and SAD-60 (HR=8.850, 95% CI=1.035-75.696; p=0.046) were independent risk factors for mortality. Conclusion: SAD-60 and FIB-4 scores are easily applicable and may be used to predict mortality in COVID-19 patients. Keywords: APRI, FIB-4, SAD-160, COVID-19, mortality, predictors

show abstract

Validation externe des scores pronostiques de la Covid-19 en hospitalisation : une étude de cohorte multicentrique

Cited by 2 publications

References 0 publications

External Validation of the COVID-NoLab and COVID-SimpleLab Prognostic Tools

External Validation of the COVID-NoLab and COVID-SimpleLab Prognostic Tools

The Role of APRI, FIB-4, and SAD-60 Scores as Predictors of Mortality in COVID-19 Patients

Contact Info

Product

Resources

About